Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Health system perspective regarding glycoprotein IIb/IIIa inhibitor therapy.
Schrogie
J J
JJ
Jefferson Medical College, Philadelphia, PA, USA.
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D005569:Formularies as Topic; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000191:economics / Q000627:therapeutic use*; D010606:Pharmacy and Therapeutics Committee; D010975:Platelet Aggregation Inhibitors / Q000191:economics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*; D014481:United States
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab